Immuneering doses first patient in phase 3 pancreatic cancer trial

June 11, 2026 7:30 AM

Immuneering Corporation (NASDAQ: IMRX) announced that the first patient has been dosed in its MAPKeeper 301 phase 3 clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found